tb immunotherapy collaboration agreement

6/14/2011

TB Immunotherapy Collaboration Agreement With Stirling Products and Zodiac Capital





(PressMethod) - Immune Network Ltd. (Pink Sheets:IMMFF - News) advises that it has entered into a conditional agreement with Australian-based Stirling Products Limited (ASX:STI - News) and Zodiac Capital Limited (NSX:ZOD) (the Australian partners) with regard to an improved formulation of Immunoxel/Dzherelo recently developed and clinically tested by the Company.

The new sublingual tablet formulation has already demonstrated potential for improved effectiveness. Importantly, the decreased cost of production, improved stability and ease of use of the new Immunoxel/Dzherelo formulation is likely to improve the accessibility and availability of the product for TB patients.


TB Immunotherapy Collaboration Agreement